Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | GAK | O14976 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424161 | 1.00 | NPY5R (0.45) | NPY5RTSHRMAPK1MAPTGSK3B | |
| SCHEMBL10114350 | 1.00 | NPY5R (0.45) | NPY5RTSHRMAPK1MAPTGSK3B | |
| SCHEMBL13204150 | 1.00 | NPY5R (0.45) | NPY5RTSHRMAPK1MAPTGSK3B | |
| SCHEMBL10114730 | 0.87 | TSHR (0.37) | NPY5RTSHRMAPK1MAPTGSK3B | |
| SCHEMBL13204301 | 0.87 | TSHR (0.37) | NPY5RTSHRMAPK1MAPTGSK3B | |
| SCHEMBL10134102 | 0.87 | TSHR (0.37) | NPY5RTSHRMAPK1MAPTGSK3B | |
| SCHEMBL10115567 | 0.84 | USP30 (0.33) | NPY5RUSP30 | |
| SCHEMBL10133271 | 0.84 | USP30 (0.33) | NPY5RUSP30 | |
| SCHEMBL13972721 | 0.81 | TSHR (0.43) | TSHRMAPK1MAPTGSK3BBRAF | |
| SCHEMBL10114332 | 0.80 | NPY5R (0.47) | NPY5RTSHRMAPTGSK3BBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | NPY5R 1/4885TSHR 189/4885MAPK1 1345/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | NPY5R 1/4885TSHR 173/4885MAPK1 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.